U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Orange Book Home

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for ANDA 212287

Expand all

PIPERACILLIN AND TAZOBACTAM (PIPERACILLIN SODIUM; TAZOBACTAM SODIUM)
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL
Marketing Status: Discontinued
Active Ingredient: PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Proprietary Name: PIPERACILLIN AND TAZOBACTAM
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A212287
Product Number: 001
Approval Date: Jul 29, 2019
Applicant Holder Full Name: ASTRAL STERITECH PVT LTD
Marketing Status:  Discontinued
Patent and Exclusivity Information
PIPERACILLIN AND TAZOBACTAM (PIPERACILLIN SODIUM; TAZOBACTAM SODIUM)
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL
Marketing Status: Discontinued
Active Ingredient: PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Proprietary Name: PIPERACILLIN AND TAZOBACTAM
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A212287
Product Number: 002
Approval Date: Jul 29, 2019
Applicant Holder Full Name: ASTRAL STERITECH PVT LTD
Marketing Status:  Discontinued
Patent and Exclusivity Information
PIPERACILLIN AND TAZOBACTAM (PIPERACILLIN SODIUM; TAZOBACTAM SODIUM)
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL
Marketing Status: Discontinued
Active Ingredient: PIPERACILLIN SODIUM; TAZOBACTAM SODIUM
Proprietary Name: PIPERACILLIN AND TAZOBACTAM
Dosage Form; Route of Administration: INJECTABLE; INJECTION
Strength: EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL
Reference Listed Drug: No
Reference Standard: No
TE Code: 
Application Number: A212287
Product Number: 003
Approval Date: Jul 29, 2019
Applicant Holder Full Name: ASTRAL STERITECH PVT LTD
Marketing Status:  Discontinued
Patent and Exclusivity Information
Back to Top